MiniMed Study Links More Alert Responses To Better Diabetes Control
MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today presented new clinical evidence showing that people with type 1 diabetes using the MiniMed Smart MDI system who responded to more missed-dose and
MiniMed found that diabetes patients who pay attention to alerts do better. When you see a company prove its product actually helps people, that shows real value.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.